Nektar Therapeutics (NKTR) Gross Profit (2010 - 2026)

Nektar Therapeutics' Gross Profit history runs 17 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 146.46% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $37.6 million, a 32.45% increase from a year earlier, with the FY2025 full-year figure at $55.2 million, down 2.04% from the prior year.
• Gross Profit fell to $3.2 million in Q1 2026 per NKTR's latest filing, from $21.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $21.8 million in Q4 2025 and bottomed at -$6.8 million in Q1 2025.
• The 5-year median for Gross Profit is $13.1 million (2024), against an average of $11.8 million.
• Across the five-year window, Gross Profit tumbled 165.17% in 2025 and soared 146.46% in 2026, its largest moves.
• Year by year, Gross Profit stood at $15.8 million in 2022, then fell by 15.63% to $13.3 million in 2023, then fell by 26.16% to $9.8 million in 2024, then soared by 121.68% to $21.8 million in 2025, then sank by 85.51% to $3.2 million in 2026.
• Per Business Quant, the three latest NKTR Gross Profit figures stand at $3.2 million (Q1 2026), $21.8 million (Q4 2025), and $1.5 million (Q3 2025).